These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 28419408

  • 1. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study.
    Musto P, Maurillo L, Simeon V, Poloni A, Finelli C, Balleari E, Ricco A, Rivellini F, Cortelezzi A, Tarantini G, Villani O, Mansueto G, Milella MR, Scapicchio D, Marziano G, Breccia M, Niscola P, Sanna A, Clissa C, Voso MT, Fenu S, Venditti A, Santini V, Angelucci E, Levis A.
    Br J Haematol; 2017 Jun; 177(5):741-750. PubMed ID: 28419408
    [Abstract] [Full Text] [Related]

  • 2. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [Abstract] [Full Text] [Related]

  • 3. Deferasirox chelation therapy in patients with transfusion-dependent MDS: a 'real-world' report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata.
    Maurillo L, Breccia M, Buccisano F, Voso MT, Niscola P, Trapè G, Tatarelli C, D'Addosio A, Latagliata R, Fenu S, Piccioni AL, Fragasso A, Aloe Spiriti MA, Refrigeri M, Criscuolo M, Musto P, Venditti A.
    Eur J Haematol; 2015 Jul; 95(1):52-6. PubMed ID: 25764148
    [Abstract] [Full Text] [Related]

  • 4. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S.
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [Abstract] [Full Text] [Related]

  • 5. Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population.
    Breccia M, Finsinger P, Loglisci G, Federico V, Santopietro M, Colafigli G, Petrucci L, Salaroli A, Serrao A, Latagliata R, Alimena G.
    Ann Hematol; 2012 Sep; 91(9):1345-9. PubMed ID: 22569854
    [Abstract] [Full Text] [Related]

  • 6. Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.
    Del Corso L, Biale L, Parodi EL, Russo R, Filiberti R, Arboscello E.
    Int J Clin Oncol; 2017 Apr; 22(2):380-386. PubMed ID: 27771776
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.
    Gattermann N, Jarisch A, Schlag R, Blumenstengel K, Goebeler M, Groschek M, Losem C, Procaccianti M, Junkes A, Leismann O, Germing U.
    Eur J Haematol; 2012 Mar; 88(3):260-8. PubMed ID: 22023452
    [Abstract] [Full Text] [Related]

  • 8. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.
    List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E.
    J Clin Oncol; 2012 Jun 10; 30(17):2134-9. PubMed ID: 22547607
    [Abstract] [Full Text] [Related]

  • 9. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
    Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E.
    BMJ Support Palliat Care; 2016 Mar 10; 6(1):80-8. PubMed ID: 25204541
    [Abstract] [Full Text] [Related]

  • 10. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF, Arrizabalaga B, Del Cañizo C, Sanz G, Villegas A.
    Ann Hematol; 2010 Feb 10; 89(2):147-54. PubMed ID: 19690857
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
    Kim IH, Moon JH, Lim SN, Sohn SK, Kim HG, Lee GW, Kim YS, Lee HS, Kwon KY, Kim SH, Park KT, Chung JS, Lee WS, Lee SM, Hyun MS, Kim H, Ryoo HM, Bae SH, Joo YD.
    Transfusion; 2015 Jul 10; 55(7):1613-20. PubMed ID: 25764017
    [Abstract] [Full Text] [Related]

  • 12. Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?
    Wong SA, Leitch HA.
    Leuk Res; 2018 Jan 10; 64():24-29. PubMed ID: 29149650
    [Abstract] [Full Text] [Related]

  • 13. [The role of iron metabolism in myelodysplastic syndromes].
    Finelli C, Clissa C, Stanzani M.
    Recenti Prog Med; 2014 Mar 10; 105(3):123-6. PubMed ID: 24675455
    [Abstract] [Full Text] [Related]

  • 14. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep 10; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 15. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S, Kobune M, Iyama S, Sato T, Murase K, Kawano Y, Takada K, Ono K, Kaneko Y, Miyanishi K, Sato Y, Hayashi T, Takimoto R, Kato J.
    Free Radic Biol Med; 2012 Aug 15; 53(4):643-8. PubMed ID: 22705364
    [Abstract] [Full Text] [Related]

  • 16. Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox.
    Nolte F, Angelucci E, Beris P, Macwhannell A, Selleslag D, Schumann C, Xicoy B, Almeida A, Guerci-Bresler A, Sliwa T, Muus P, Porter J, Hofmann WK.
    Leuk Res; 2011 Sep 15; 35(9):1131-5. PubMed ID: 21737138
    [Abstract] [Full Text] [Related]

  • 17. Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
    Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM.
    Oncologist; 2009 May 15; 14(5):489-96. PubMed ID: 19365094
    [Abstract] [Full Text] [Related]

  • 18. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.
    Ann Hematol; 2011 Jun 15; 90(6):655-66. PubMed ID: 21318574
    [Abstract] [Full Text] [Related]

  • 19. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.
    Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ.
    J Comp Eff Res; 2015 Aug 15; 4(4):327-40. PubMed ID: 26274794
    [Abstract] [Full Text] [Related]

  • 20. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
    Cermak J, Jonasova A, Vondrakova J, Cervinek L, Belohlavkova P, Neuwirtova R.
    Leuk Res; 2013 Dec 15; 37(12):1612-5. PubMed ID: 23937987
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.